Tags

Type your tag names separated by a space and hit enter

Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome.
Retina. 2007 Apr-May; 27(4):458-61.R

Abstract

PURPOSE

To evaluate the efficacy of photodynamic therapy (PDT) and high-dose intravitreal triamcinolone acetonide (TA) injection to treat choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) at the 2-year follow-up.

METHODS

In this prospective, consecutive, comparative, nonrandomized, interventional case series, 30 eyes of 30 consecutive patients with subfoveal CNV associated with AMD were treated by PDT followed by intravitreal injection of 19.4 +/- 2.1 mg TA. Fifteen eyes were naive to treatment (group 1), and 15 had been treated previously by PDT alone (group 2). A group of 15 eyes of 15 patients treated by PDT alone served as controls. The number of Snellen lines gained or lost and PDT sessions were evaluated.

RESULTS

Best-corrected visual acuity (BCVA) did not change significantly in group 1 from baseline (0.0 +/- 3.4 Snellen line; range, -5 to 9 Snellen lines; P = 0.81); group 2 lost an average -0.6 +/- 2.5 line (range, -7 to 3 Snellen lines) (P = 0.41), and the control group lost an average of -2.2 +/- 3.4 lines (range, -8 to 2 Snellen lines) (P = 0.03, Wilcoxon signed rank test). The average number of PDT sessions during the 24-month follow-up was 1.9, 1.2, and 3.9 for group 1, group 2, and the control group, respectively.

CONCLUSION

Two years after combined PDT/high-dose intravitreal TA to treat AMD-associated CNV, final BCVA was stable, and the need for retreatment was reduced compared with historical controls.

Authors+Show Affiliations

Department of Ophthalmology, Miguel Hernández University School of Medicine, Alicante, Spain. jm.ruiz@umh.esNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17420698

Citation

Ruiz-Moreno, José M., et al. "Photodynamic Therapy and High-dose Intravitreal Triamcinolone to Treat Exudative Age-related Macular Degeneration: 2-year Outcome." Retina (Philadelphia, Pa.), vol. 27, no. 4, 2007, pp. 458-61.
Ruiz-Moreno JM, Montero JA, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. Retina (Philadelphia, Pa). 2007;27(4):458-61.
Ruiz-Moreno, J. M., Montero, J. A., & Zarbin, M. A. (2007). Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. Retina (Philadelphia, Pa.), 27(4), 458-61.
Ruiz-Moreno JM, Montero JA, Zarbin MA. Photodynamic Therapy and High-dose Intravitreal Triamcinolone to Treat Exudative Age-related Macular Degeneration: 2-year Outcome. Retina (Philadelphia, Pa). 2007;27(4):458-61. PubMed PMID: 17420698.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. AU - Ruiz-Moreno,José M, AU - Montero,Javier A, AU - Zarbin,Marco A, PY - 2007/4/11/pubmed PY - 2007/5/16/medline PY - 2007/4/11/entrez SP - 458 EP - 61 JF - Retina (Philadelphia, Pa.) JO - Retina (Philadelphia, Pa.) VL - 27 IS - 4 N2 - PURPOSE: To evaluate the efficacy of photodynamic therapy (PDT) and high-dose intravitreal triamcinolone acetonide (TA) injection to treat choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) at the 2-year follow-up. METHODS: In this prospective, consecutive, comparative, nonrandomized, interventional case series, 30 eyes of 30 consecutive patients with subfoveal CNV associated with AMD were treated by PDT followed by intravitreal injection of 19.4 +/- 2.1 mg TA. Fifteen eyes were naive to treatment (group 1), and 15 had been treated previously by PDT alone (group 2). A group of 15 eyes of 15 patients treated by PDT alone served as controls. The number of Snellen lines gained or lost and PDT sessions were evaluated. RESULTS: Best-corrected visual acuity (BCVA) did not change significantly in group 1 from baseline (0.0 +/- 3.4 Snellen line; range, -5 to 9 Snellen lines; P = 0.81); group 2 lost an average -0.6 +/- 2.5 line (range, -7 to 3 Snellen lines) (P = 0.41), and the control group lost an average of -2.2 +/- 3.4 lines (range, -8 to 2 Snellen lines) (P = 0.03, Wilcoxon signed rank test). The average number of PDT sessions during the 24-month follow-up was 1.9, 1.2, and 3.9 for group 1, group 2, and the control group, respectively. CONCLUSION: Two years after combined PDT/high-dose intravitreal TA to treat AMD-associated CNV, final BCVA was stable, and the need for retreatment was reduced compared with historical controls. SN - 0275-004X UR - https://www.unboundmedicine.com/medline/citation/17420698/Photodynamic_therapy_and_high_dose_intravitreal_triamcinolone_to_treat_exudative_age_related_macular_degeneration:_2_year_outcome_ L2 - http://dx.doi.org/10.1097/IAE.0b013e318030c77c DB - PRIME DP - Unbound Medicine ER -